Literature DB >> 30370103

Atezolizumab in non-squamous non-small cell lung cancer.

Takaki Akamine1, Gouji Toyokawa1, Tetsuzo Tagawa1, Takashi Seto2.   

Abstract

Entities:  

Year:  2018        PMID： 30370103      PMCID： PMC6186653          DOI： 10.21037/jtd.2018.07.92

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

Review 1.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Authors:  Monica Khunger; Sagar Rakshit; Vinay Pasupuleti; Adrian V Hernandez; Peter Mazzone; James Stevenson; Nathan A Pennell; Vamsidhar Velcheti
Journal:  Chest       Date:  2017-05-10       Impact factor: 9.410

2.  Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Authors:  Betty Li; Alshad S Lalani; Thomas C Harding; Bo Luan; Kathryn Koprivnikar; Guang Huan Tu; Rodney Prell; Melinda J VanRoey; Andrew D Simmons; Karin Jooss
Journal:  Clin Cancer Res       Date:  2006-11-15       Impact factor: 12.531

Review 3.  The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Authors:  Christian Manegold; Anne-Marie C Dingemans; Jhanelle E Gray; Kazuhiko Nakagawa; Marianne Nicolson; Solange Peters; Martin Reck; Yi-Long Wu; Odd Terje Brustugun; Lucio Crinò; Enriqueta Felip; Dean Fennell; Pilar Garrido; Rudolf M Huber; Aurélien Marabelle; Marcin Moniuszko; Françoise Mornex; Silvia Novello; Mauro Papotti; Maurice Pérol; Egbert F Smit; Kostas Syrigos; Jan P van Meerbeeck; Nico van Zandwijk; James Chih-Hsin Yang; Caicun Zhou; Everett Vokes
Journal:  J Thorac Oncol       Date:  2016-10-08       Impact factor: 15.609

4.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

5.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

6.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

Review 7.  Control of the immune response by pro-angiogenic factors.

Authors:  Thibault Voron; Elie Marcheteau; Simon Pernot; Orianne Colussi; Eric Tartour; Julien Taieb; Magali Terme
Journal:  Front Oncol       Date:  2014-04-02       Impact factor: 6.244

8.  FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.

Authors:  Lee Pai-Scherf; Gideon M Blumenthal; Hongshan Li; Sriram Subramaniam; Pallavi S Mishra-Kalyani; Kun He; Hong Zhao; Jingyu Yu; Mark Paciga; Kirsten B Goldberg; Amy E McKee; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2017-08-23

9.  Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Authors:  George N Naumov; Monique B Nilsson; Tina Cascone; Alexandra Briggs; Oddbjorn Straume; Lars A Akslen; Eugene Lifshits; Lauren Averett Byers; Li Xu; Hua-Kang Wu; Pasi Jänne; Susumu Kobayashi; Balazs Halmos; Daniel Tenen; Xi M Tang; Jeffrey Engelman; Beow Yeap; Judah Folkman; Bruce E Johnson; John V Heymach
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245
View more
  2 in total

Review 1.  Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy.

Authors:  Simran Venkatraman; Jarek Meller; Suradej Hongeng; Rutaiwan Tohtong; Somchai Chutipongtanate
Journal:  Vaccines (Basel)       Date:  2020-12-04

Review 2.  Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.

Authors:  Jing Chen; Yaser Alduais; Baoan Chen
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.